Treatment Emergent Definitions Recommendations

Project Scope

This Project team will create a White Paper with recommendations for Treatment Emergent Definitions, with a focus on Phase 2-4 clinical trials. This White Paper will build upon a White Paper that outlines results from a survey on current practices, indicating variation that can likely be reduced. Recommendations will be based on the desired end-in-mind, and may or may not be consistent with current practices.

Project LeadsEmails

William Palo, Abbvie

william.palo@abbvie.com

Nicola Newton, PHUSE Project Assistant

nicky@phuse.global

CURRENT STATUS Q3 2024

  • Engaged graphics vendor to start finalisation of white paper.

Objectives & Deliverables 

Timelines 

White Paper - Recommended Definition of Treatment-Emergent Adverse Events in Clinical Trials'

Q3 2024